Hey traders, Lance Ippolito here! Welcome to our Weekly Rundown, where we’ll share some of our top trading ideas — and our biggest winners!
If the world wants to reduce its carbon footprint in hopes of reaching net-zero emissions by 2050, it’s going to take a lot.
Sure, that means we need more renewables like solar panels, wind turbines and hydroelectric power…
The whole endeavor is a heck of a lot more involved than just slapping it all on the power grid as it exists and calling it a day.
To truly replace that infrastructure, we’re going to have to replace baseload power plants that have the ability to increase the amount of juice they pump out on demand.
So we’re going to need batteries — loads and loads of them.
Batteries in our homes, cars and in the power grid, which means a lot of green for lithium mining stocks.
Lithium Mining Stocks: The Revolution Will Be Monetized
The entire power grid, however, isn’t ready for prime time just yet. So let’s take a step back and figure out what it would take to solve a smaller problem — electrifying the driving fleet.
At the moment, it takes roughly a ton of lithium to build around 90 electric cars.
In the years leading up to the pandemic, global new car sales totalled about 97 million units. So to completely replace that figure, it will take about 1.07 million tons of lithium metal.
If we want to meet that mark, some napkin math suggests we would need to increase lithium production by about tenfold from where it sits now.
Lithium is one of the cornerstones needed to solve this problem, and it’s going to take a lot of time and money to build out the infrastructure. As that happens, there are going to be loads of opportunities to capitalize on this trend.
One such opportunity is Lithium Americas Corp. (NYSE: LAC). This firm has operations in Nevada and Argentina. I’m seeing a lot of options flow to the bullish side including a ton of calls that expire in September and November.
I’m already nibbling on this one. But if the market ever pulls back, this stock is at the top of my shopping list.
The story with HP Inc. (NYSE: HPQ) began back at the start of August when shares hovered around the $29 mark. With the stock retreating toward its 50-day moving average and earnings set to report on Aug. 26, bears took aim on the September monthly $30 strike puts. In all, they picked up over 6,000 contracts for a total of $1.1 million in premium.
That Aug. 4 buy caught the attention of the Blitz Tracker, and the alert went out to members immediately. The bears came back for more on Tuesday, this time taking $4.2 million worth of the Aug. 27 $30 strike puts — live in front of my War Room watchers! The stock continued its breakdown while Weekly Blitz Alerts and Daily Profits Challenge members collected those profits!
+31.58% and 50% on two halves of HPQ Sept. 17 $30 PUT.
Entered on Aug. 4 at $1.90 a contract.
Exited on Aug.18 at $2.50 and $2.85 a contract.
+43.33% on the first half of HPQ Aug. 27 $30 PUT.
Entered on Aug. 17 at $1.50 a contract.
Exited on Aug.18 at $2.15 a contract.
Meanwhile, over at Blockbuster Breakout Calendar, our patience was finally rewarded on Gilead Sciences Inc. (Nasdaq: GILD). On July 16, GILD saw strong repeat buying of its November monthly $70 strike calls for a total bet just north of $1 million. The long date on those calls were important here, as Gilead will find out if its new cancer treatment will see FDA approval by Oct. 1. After weeks of trading sideways, the biotech sector picked up with COVID-19 cases on the rise again. The stock broke higher on Monday and the alert went out to Blockbuster members to cash out for another solid win!
+38.98% on GILD Nov. 19 $70 CALL.
Entered on July 16 at $2.95 a contract.
Exited on Aug. 16 at $4.10 a contract.
With a nice win in GILD already in pocket for Blockbuster Breakout Calendar members on Monday, Tuesday’s win was the cherry on top. On Aug. 11, the bulls jumped on the Merck & Co. Inc. (NYSE: MRK) Nov. 19 $80 strike call. Traders swept up contracts in 500-plus lots ahead of Merck’s upcoming FDA review dates for a combination treatment of its Keytruda and Lenvima cancer drugs on Aug. 25 and 26.
In addition to rising pandemic-driven tides for biotech, Merck saw FDA approval of another cancer treatment, Welireg, helping shares climb around 3% on the week. The move helped slingshot the November calls and Blockbuster members started the week off with a BANG!
+58.3% and 100% on two halves of MRK Nov. 19 $80 CALL.
Entered on Aug. 11 at $1.20 a contract.
Exited on Aug. 16 at $1.90 a contract.
Exited on Aug. 17 at $2.40 a contract.
Be sure and check out our Weekly Blitz Alerts,Daily Profits Challenge and Blockbuster Breakout Calendar for more BIG winners like this!
California Man Bets $3.4M of His Own Money
Former Air Force pilot, 10-time Trading Champion and million-dollar investor Chuck Hughes is revealing his brand-new discovery, Omega One…
Not only will he reveal this pricing anomaly that has recently paid him 104 times out of 108 trades…
But he’s going to put $3.4 million on the line to help you succeed with this new formula!
If you’re looking for more compelling trade ideas and stock market musings to read and help you prepare for what lies ahead, here’s what other experts at WealthPress are saying:
Disclaimer & Disclosures The information in this email is intended for informational purposes only and does not guarantee specific results as there is a high degree of risk involved with trading. Also, our traders are real traders and may have financial interests in the companies discussed. Please see our Terms and Conditions for more information.
0 Response to "Weekly Rundown: A ‘Green Revolution’ Stock at the Top of My Shopping List"
Post a Comment